Literature DB >> 32452762

SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.

Praveen Anand1, Arjun Puranik2, Murali Aravamudan2, A J Venkatakrishnan2, Venky Soundararajan2.   

Abstract

Molecular mimicry is an evolutionary strategy adopted by viruses to exploit the host cellular machinery. We report that SARS-CoV-2 has evolved a unique S1/S2 cleavage site, absent in any previous coronavirus sequenced, resulting in the striking mimicry of an identical FURIN-cleavable peptide on the human epithelial sodium channel α-subunit (ENaC-α). Genetic alteration of ENaC-α causes aldosterone dysregulation in patients, highlighting that the FURIN site is critical for activation of ENaC. Single cell RNA-seq from 66 studies shows significant overlap between expression of ENaC-α and the viral receptor ACE2 in cell types linked to the cardiovascular-renal-pulmonary pathophysiology of COVID-19. Triangulating this cellular characterization with cleavage signatures of 178 proteases highlights proteolytic degeneracy wired into the SARS-CoV-2 lifecycle. Evolution of SARS-CoV-2 into a global pandemic may be driven in part by its targeted mimicry of ENaC-α, a protein critical for the homeostasis of airway surface liquid, whose misregulation is associated with respiratory conditions.
© 2020, Anand et al.

Entities:  

Keywords:  COVID-19; ENaC; SARS-CoV-2; acute respiratory distress syndrome; computational biology; coronavirus; human; human biology; medicine; molecular mimicry; mouse; systems biology; virus

Mesh:

Substances:

Year:  2020        PMID: 32452762      PMCID: PMC7343387          DOI: 10.7554/eLife.58603

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


Introduction

The surface of SARS-CoV-2 virions is coated with the spike (S) glycoprotein, whose proteolysis is key to the infection lifecycle. After the initial interaction of the S-protein with the ACE2 receptor (Walls et al., 2020), host cell entry is mediated by two key proteolytic steps. The S1 subunit of the S-protein engages ACE2, and viral entry into the host cell is facilitated by proteases that catalyze S1/S2 cleavage (Belouzard et al., 2012; Belouzard et al., 2009) at Arginine-667/Serine-668 (Figure 1a). This is followed by S2’ site cleavage that is required for fusion of viral-host cell membranes (Hoffmann et al., 2020; Walls et al., 2020).
Figure 1.

Targeted molecular mimicry by SARS-CoV-2 of human ENaC-ɑ and profiling ACE2-FURIN-ENaC-ɑ co-expression.

(a) The cartoon representation of the S-protein homotrimer from SARS-CoV-2 is shown (PDB ID: 6VSB). One of the monomers is highlighted in red. The alignment of the S1/S2 cleavage site required for the activation of SARS-CoV-2, SARS-CoV, Pangolin-CoV, and Bat-CoV RaTG13 are shown. The four amino acid insertion evolved by SARS-CoV-2, along with the abutting cleavage site is shown in a box. (b) The cartoon representation of human ENaC protein is depicted (PDB ID: 6BQN; chain in green), highlighting the ENaC-ɑ chain in green. The alignment on the right captures FURIN cleavage at the S1/S2 site of SARS-CoV-2, along with its striking molecular mimicry of the identical peptide from human ENaC-ɑ protein (dotted loop in the cartoon rendering of human ENaC). The alignment further shows the equivalent 8-mer peptide of mouse ENaC-ɑ that is also known to be cleaved by FURIN. One of the known genetic alterations on human ENaC-ɑ is highlighted as well (Welzel et al., 2013). (c) The single cell transcriptomic co-expression of ACE2, ENaC-ɑ, and FURIN is summarized. The heatmap depicts the mean relative expression of each gene across the identified cell populations. The human and mouse single cell RNA-seq are visualized independently. The cell types are ranked based on decreasing expression of ACE2. The box highlights the ACE2 positive cell types in human and mouse samples.

Targeted molecular mimicry by SARS-CoV-2 of human ENaC-ɑ and profiling ACE2-FURIN-ENaC-ɑ co-expression.

(a) The cartoon representation of the S-protein homotrimer from SARS-CoV-2 is shown (PDB ID: 6VSB). One of the monomers is highlighted in red. The alignment of the S1/S2 cleavage site required for the activation of SARS-CoV-2, SARS-CoV, Pangolin-CoV, and Bat-CoV RaTG13 are shown. The four amino acid insertion evolved by SARS-CoV-2, along with the abutting cleavage site is shown in a box. (b) The cartoon representation of human ENaC protein is depicted (PDB ID: 6BQN; chain in green), highlighting the ENaC-ɑ chain in green. The alignment on the right captures FURIN cleavage at the S1/S2 site of SARS-CoV-2, along with its striking molecular mimicry of the identical peptide from human ENaC-ɑ protein (dotted loop in the cartoon rendering of human ENaC). The alignment further shows the equivalent 8-mer peptide of mouse ENaC-ɑ that is also known to be cleaved by FURIN. One of the known genetic alterations on human ENaC-ɑ is highlighted as well (Welzel et al., 2013). (c) The single cell transcriptomic co-expression of ACE2, ENaC-ɑ, and FURIN is summarized. The heatmap depicts the mean relative expression of each gene across the identified cell populations. The human and mouse single cell RNA-seq are visualized independently. The cell types are ranked based on decreasing expression of ACE2. The box highlights the ACE2 positive cell types in human and mouse samples.

Results

We hypothesized that the virus may mimic host substrates to achieve proteolysis. Comparing human-infecting SARS-CoV-2 with SARS-CoV strains, as well as with candidates of zoonotic origin (Pangolin-CoV and Bat-CoV RaTG13), shows that SARS-CoV-2 has evolved a unique sequence insertion at the S1/S2 site (Zhang et al., 2020; Figure 1a). Although the S protein of SARS-CoV-2 shares high sequence identity with the S proteins of Pangolin-CoV (92%) and Bat-CoV RaTG13 (97%), the furin insertion site seems to be uniquely acquired by SARS-CoV-2. The resulting tribasic 8-mer peptide (RRARSVAS) on the SARS-CoV-2 S1/S2 site is conserved among 10,956 of 10,967 circulating strains deposited at GISAID (https://www.gisaid.org/) (Elbe and Buckland-Merrett, 2017), as of April 28, 2020 (Supplementary file 1a). This peptide is also absent in over 13,000 non-COVID-19 coronavirus S-proteins from the VIPR database (Carrillo-Tripp et al., 2009). Strikingly, examining over 10 million peptides (8-mers) of 20,350 canonical human proteins from UniProtKB shows that the peptide of interest (RRARSVAS) is present exclusively in human ENaC-ɑ, also known as SCNN1A (p-value=4E-4) (see Materials and methods). The location of this SARS-CoV-2 mimicked peptide in the ENaC-ɑ structure is in the extracellular domain (Noreng et al., 2018; Figure 1b). This suggests that the SARS-CoV-2 may have specifically evolved to mimic a human protease substrate. ENaC regulates sodium ion (Na+) and water homeostasis, and ENaC’s expression levels are controlled by aldosterone and the associated Renin-Angiotensin-Aldosterone System (RAAS)6. In distal lung airways, ENaC is known to play a key role in controlling fluid reabsorption at the air–liquid interface (Rossier and Stutts, 2009), and similar to SARS-CoV2, ENaC-ɑ also needs to be proteolytically activated for its function (Vallet et al., 1997). FURIN cleaves the equivalent peptide on mouse ENaCbetween the Arginine and Serine residues in the 4th and 5th positions respectively (RSAR|SASS) (Hughey et al., 2004a; Hughey et al., 2004b), akin to the recent report establishing FURIN cleavage at the S1/S2 site of SARS-CoV-2 (Walls et al., 2020; Figure 1b). It is conceivable that human ENaC activation may be compromised in SARS-CoV-2 infected cells, for instance by SARS-CoV-2 exploiting host FURIN for its own activation. The likely consequence would be low ENaC activity on the surface of the airways leading to compromised fluid reabsorption (Planès et al., 2010; Yurdakök, 2010), an important lung pathology in COVID-19 patients with acute respiratory distress syndrome (ARDS). Indeed, the exact mechanism of SARS-CoV-2’s potential impact of ENaC activation needs to be investigated. Although the furin-like cleavage motifs can be found in other viruses (Coutard et al., 2020), the exact mimicry of human ENaC-ɑ cleavage site raises the specter that SARS-CoV-2 may be hijacking the protease network of ENaC-ɑ for viral activation. We asked whether there is an overlap between putative SARS-CoV-2 infecting cells and ENaC-ɑ expressing cells. Systematic single cell expression profiling of the ACE2 receptor and ENaC-ɑ was performed across human and mouse samples comprising ~1.3 million cells (Venkatakrishnan et al., 2020; Figure 1c). Interestingly, ENaC-ɑ is expressed in the nasal epithelial cells, type II alveolar cells of the lungs, tongue keratinocytes, and colon enterocytes (Figure 1c and Figure 2—figure supplements 1–6), which are all implicated in COVID-19 pathophysiology (Shweta et al., 2020; Venkatakrishnan et al., 2020). Further, ACE2 and ENaC-ɑ are known to be expressed generally in the apical membranes of polarized epithelial cells (Butterworth, 2010; Musante et al., 2019). The overlap of the cell-types expressing ACE2 and ENaC-ɑ, and similar spatial distributions at the apical surfaces, suggest that SARS-CoV-2 may be leveraging the protease network responsible for ENaC cleavage.
Figure 2—figure supplement 1.

Cardiomyocytes express ENaC-ɑ (SCNN1A) and ACE2 (Primary data processed from Pubmed ID:31915373 and hosted on https://academia.nferx.com/).

Figure 2—figure supplement 6.

Colon enterocytes express SCNN1A (ENaC-ɑ) and ACE2 (Primary data processed from Pubmed ID:31348891 and hosted on https://academia.nferx.com/).

Beyond FURIN, which cleaves the S1/S2 site (Walls et al., 2020), we were intrigued by the possibility of other host proteases also being exploited by SARS-CoV-2. We created a 160-dimensional vector space (20 amino acids x eight positions on the peptide) for assessment of cleavage similarities between the 178 human proteases with biochemical validation from the MEROPS database (see Materials and methods; 0 < protease similarity metric <1) (Rawlings et al., 2018). This shows that FURIN (PCSK3) has overall proteolytic similarity to select PCSK family members, specifically PCSK5 (0.99), PCSK7 (0.99), PCSK6 (0.99), PCSK4 (0.98), and PCSK2 (0.94) (Supplementary file 1b). It is also known that the protease PLG cleaves the ɣ-subunit of ENaC (ENaC-ɣ)(Passero et al., 2008). In order to extrapolate the tissue tropism of SARS-CoV-2 from the lens of the host proteolytic network, we assessed the co-expression of these proteases concomitant with the viral receptor ACE2 and ENaC-ɑ (Figure 2). This analysis shows that FURIN is expressed with ACE2 and ENaC-ɑ in the colon (immature enterocytes, transit amplifying cells) and pancreas (ductal cells, acinar cells) of human tissues, as well as tongue (keratinocytes) of mouse tissues. PCSK5 and PCSK7 are broadly expressed across multiple cell types with ACE2 and ENaC-ɑ, making it a plausible broad-spectrum protease that may cleave the S1/S2 site. In humans, concomitant with ACE2 and ENaC-ɑ, PCSK6 appears to be expressed in cells from the intestines, pancreas, and lungs, whereas PCSK2 is noted to be co-expressed in the pancreas (Figure 2). It is worth noting that the extracellular proteases need not necessarily be expressed in the same cells as ACE2 and ENaC-ɑ. Among the PCSK family members with the potential to cleave the mimicked 8-mer peptide, it is intriguing that the same tissue can house multiple proteases and also that multiple tissues do share the same set of proteases.
Figure 2.

Expression profiling of identified proteases.

The heatmap depicts the relative expression of ACE2 and ENaC-ɑ along with a list of proteases that can potentially cleave the S1/S2 site. The relative expression levels are denoted on a scale of blue (low) to red (high). The rows denote proteases and columns denote cell-types.

Although only 2.77% of the proximal tubule cells had detectable expression of SCNN1A, a higher percentage (8.46%) of these cells were also observed to express ACE2 (Primary data processed from Pubmed ID: 31604275 and hosted on https://academia.nferx.com/).

Expression profiling of identified proteases.

The heatmap depicts the relative expression of ACE2 and ENaC-ɑ along with a list of proteases that can potentially cleave the S1/S2 site. The relative expression levels are denoted on a scale of blue (low) to red (high). The rows denote proteases and columns denote cell-types.

Higher expression of SCNN1A was detected in 58% of the principal cells in the collecting duct 47% of the connecting tubule cells from the kidney, but ACE2 expression was not detected in these cell types.

Although only 2.77% of the proximal tubule cells had detectable expression of SCNN1A, a higher percentage (8.46%) of these cells were also observed to express ACE2 (Primary data processed from Pubmed ID: 31604275 and hosted on https://academia.nferx.com/).

Discussion

Our findings emphasize that redundancy may be wired into the mechanisms of host proteolytic activation of SARS-CoV-2. This study should stimulate the design of experiments that confirm the working hypothesis generated by our unbiased and systematic computational analysis. The mimicry of a cleavable host peptide central to pulmonary, renal, and cardiovascular function provides a new perspective to the evolution of SARS-CoV-2 in causing a global coronavirus pandemic.

Materials and methods

Alignment of coronavirus spike proteins

The complete S-protein sequence for SARS-CoV (Uniprot ID: P59594) and SARS-CoV-2 was obtained from uniprot (ftp://ftp.uniprot.org/pub/databases/uniprot/pre_release/). The sequences of Pangolin-CoV and Bat-CoV RaTG13 were obtained from the VIPR database (https://www.viprbrc.org/). Sequence alignments using Clustal-W, and comparison of SARS-CoV-2 versus other coronavirus strains were performed using JalView17.

Analysis of 8-mers of the human proteome

We enumerated 10,257,893 (10.26M) 8-mers from 20,350 reviewed uniprot reference sequences from human proteome (Proteome ID: UP000005640, as accessed on May 4th 2020). The previously identified SARS-CoV-2 8-mer ‘RRARSVAS’ was in fact found in ENaC-ɑ protein (Uniprot ID: P37088; p-value ≈ 10.26M/208 = 4E-4; chance of finding that particular 8-mer anywhere in the reference sequences).

Calculating the cosine similarity metric for protease cleavage site

The position frequency matrix (PFM) of the individual proteases obtained from the MEROPS database (Rawlings et al., 2018) was converted to a probability weight matrix (PWM) (normalized and scaled) (Supplementary file 1b). Out of 178 proteases, there were 146 proteases that had specificity information available on the eight mer peptide spanning the cleavage site (±4). The 20 (amino acids) x 8 (position) matrix defined for each of the proteases were flattened into a single vector with 160 elements. We performed a cosine similarity calculation between all pairs (X,Y) of protease specificity vector. The similarity was derived as the normalized dot product of X and Y: K(X, Y) =  / (||X||*||Y||)).

Overlap of cell types expressing ENaC-ɑ, ACE2, and proteases from scRNA-seq datasets

We performed a systematic expression profiling of the ACE2 and ENaC-ɑ across 65 published human and mouse single-cell studies comprising ~1.3 million cells using nferX Single Cell platform (Supplementary file 1c, https://academia.nferx.com/) (Venkatakrishnan et al., 2020). The ACE2 expression could be detected in 66 studies (59 studies of human samples and 7 studies of mouse samples) spanning across ~50 tissues, over 450 cell-types and ~1.05 million cells. In order to call a given cell-type to be positive for both ACE2 and a protease we applied a cutoff of 1% of the cells in the total cell-type cluster population to have a non-zero count associated with both ACE2 and the respective protease. The mean expression of the proteases, ENaC-ɑ and ACE2 was derived for individual cell population within each of the studies. The cell-type information was obtained from the author annotations provided for each of the studies. The analysis was performed separately on the mouse and human datasets. For each protease, the mean expression of given cell-population (mean log[cp10k +1] counts) was Z-score normalized (to ensure the sd = 1 and mean ~0 for all the genes) to obtain relative expression profiles across all the samples. The same normalization was applied to ACE2 and ENaC-ɑ and both human and mouse datasets were analyzed independently by generating heatmaps. The cell types having zero-expression values of ACE2 were also included as negative control to probe the expression of various proteases. We performed an analysis to identify the cell types with significant overlap of ACE2 and ENaC-ɑ expression. To this end, we shortlisted cell types in which ENaC-ɑ is expressed in a significantly higher proportion of ACE2-expressing cells than in the overall population of cells of that sub-type. We computed the ratios of these proportions, and used a corresponding Fisher exact test to compute significance. In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses. Acceptance summary: This study entails an extensive computer analyses in silico demonstrating that the amino acid sequences of the cleavage site of protein S1/S2 of the SARS-CoV2 virus, which is essential for the penetration of the virus into the host cell, corresponds exactly to the cleavage site of ENAC-α subunit. The latter is cleaved by furin, a host protease that, in doing so, activates the Na+ channel. A literature analysis carried out by the authors also indicates a significant overlap between the expression of ENAC-α and ACE2, the receptor of the virus, supporting the idea that the SARS-CoV-2 virus has evolved the identity of the cleavage peptide of ENAC-α in order to facilitate its entry inside the host cell. This paper should stimulate the design of experiments aimed at confirming the working hypothesis generated by this in silico analysis. Decision letter after peer review: Thank you for submitting your article "SARS-CoV-2 strategically mimics a cleavable pulmonary renal peptide" for consideration by eLife. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Guest Reviewing Editor and Matthias Barton, MD, as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Bernard Rossier (Reviewer #3). This decision letter is to help you prepare a revised submission. We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as eLife papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation. Summary: This study entails an in silico evaluation that demonstrates, through extensive computer analyses, that the amino acid sequences of the cleavage site of protein S1/S2 of the SARS-CoV2 virus, essential for the penetration of the virus into the host cell, corresponds exactly to the cleavage site of ENAC-α subunit. The latter is cleaved by Furin, a host protease that, in doing so, activates the Na+ channel. A literature analysis carried out by the authors also indicates a significant overlap between the expression of ENAC-α and ACE2, the receptor of the virus, supporting the idea that the SARS-CoV-2 virus has evolved the identity of the cleavage peptide of ENAC-α in order to facilitate its entry inside the host cell. Essential revisions: The information that furin is the protease that cleaves the S1/S2 site of the virus is already known (Hofmann et al., Cell, 2020 , Walls et al., 2020. The previous work noted that SARS-CoV-2 contains a polybasic furin recognition site between the S1 and S2 subunits of the spike protein. In this current study, Anand et al. identified that in addition to the furin cleavage site, SARS-CoV-2 contains an 8-mer peptide that is identical to the furin cleavage site in the α subunit of ENaC located at the C-terminal end of the putative inhibitory segment. These results are striking as they seem to suggest that the virus has evolved to cleverly trick the cells by specifically mimicking an ion channel that is known to regulate salt and water in humans. Hence, the authors should better stress the novelty of their paper, which resides in the correlation be-tween this cleavage site that is present only in SARS-CoV-2 (and not in other coronaviruses) and the ENAC-α, and by emphasizing the evolutionary aspects of their study in relation to the virus pandemics. There is one particular section in the manuscript that authors should revise. In the third paragraph, the authors overstate the importance of the defined 8-mer peptide by citing a work that identified a premature stop codon in the middle of the 8-mer peptide that truncates the α subunit giving rise to a salt-wasting disease, PHA1. The phenotype is not due to the truncation of the 8-mer peptide but is more likely due to a lack of a formation of a functional ion channel. Overall, the Authors should thus make an effort to put their findings in the context of the published literature on the control of airway surface liquid (including Rossier and Stutts, 2009). They are right in stating that genetic truncation at the ENaC-α cleavage site causes aldosterone dysregulation in patients. However, it would be important to stress that the furin site is critical for the activation of ENaC. If this activation site is blocked by mimicry of the unique S1/S2 cleavage site, its likely consequence would be very low ENaC activity on the surface of the airways, compromising severely fluid reabsorption, which can explain an important lung phenotype observed in COVID19. The so called "wet lung" syndrome, that can occur in premature babies because ENaC is only fully expressed at the time of birth, should be mentioned to support this contention. The PHA Type 1 case described in Welzel et al., 2013, also supports the importance of the furin site for ENaC activation. Additional issues: 1) The authors reported in Figure 2—figure supplement 5 ENaC expression in the proximal tubule, which is wrong as ENac is expressed only in the aldosterone sensitive distal nephron (ASDN) (Distal Convoluted Tubule DCT2, Connecting Tubule CNT and Collecting Duct CD). 2) References should be better placed and selected. For example in the second paragraph, last sentence: the structure of human ENaC (Noreng et al., 2018) should be cited here and not in the third paragraph where earlier work on structure by Vallet et al., 1997 or by Orce et al., 1980 should be cited. 3) The title is too generic and should mention ENaC rather than “a cleavable pulmonary renal peptide”. Essential revisions: The information that furin is the protease that cleaves the S1/S2 site of the virus is already known (Hofmann et al., Cell, 2020 , Walls et al., 2020. The previous work noted that SARS-CoV-2 contains a polybasic furin recognition site between the S1 and S2 subunits of the spike protein. In this current study, Anand et al. identified that in addition to the furin cleavage site, SARS-CoV-2 contains an 8-mer peptide that is identical to the furin cleavage site in the α subunit of ENaC located at the C-terminal end of the putative inhibitory segment. These results are striking as they seem to suggest that the virus has evolved to cleverly trick the cells by specifically mimicking an ion channel that is known to regulate salt and water in humans. Hence, the authors should better stress the novelty of their paper, which resides in the correlation be-tween this cleavage site that is present only in SARS-CoV-2 (and not in other coronaviruses) and the ENAC-α, and by emphasizing the evolutionary aspects of their study in relation to the virus pandemics. As suggested, we have now updated the manuscript to highlight the evolutionary aspects of our study in relation to virus pandemics. Figure 1A has been updated to compare the S1/S2 cleavage sites from human infecting SARS-CoV and SARS-CoV-2 as well as with candidates of zoonotic origin (Pangolin-CoV and Bat-CoV RatG13). We have also updated the text accordingly: “We hypothesized that the virus may mimic host substrates in order to achieve proteolysis. […] This suggests that the SARS-CoV-2 may have specifically evolved to mimic a human protease substrate.” “Although the furin-like cleavage motifs can be found in other viruses (Coutard et al., 2020), the exact mimicry of human ENaC-ɑ cleavage site raises the specter that SARS-CoV-2 may be hijacking the protease network of ENaC-ɑ for viral activation.” There is one particular section in the manuscript that authors should revise. In the third paragraph, the authors overstate the importance of the defined 8-mer peptide by citing a work that identified a premature stop codon in the middle of the 8-mer peptide that truncates the α subunit giving rise to a salt-wasting disease, PHA1. The phenotype is not due to the truncation of the 8-mer peptide but is more likely due to a lack of a formation of a functional ion channel. We thank the reviewers for this feedback. We now clarify this better: ENaC regulates sodium ion (Na+) and water homeostasis and ENaC’s expression levels are controlled by aldosterone and the associated Renin-Angiotensin-Aldosterone System (RAAS)(Elbe and Buckland-Merrett, 2017). […] The PHA1 phenotype is likely due to a lack of formation of a functional ion channel, and highlights the salience of the FURIN site for ENaC activation.” Overall, the Authors should thus make an effort to put their findings in the context of the published literature on the control of airway surface liquid (including Rossier and Stutts, 2009). They are right in stating that genetic truncation at the ENaC-α cleavage site causes aldosterone dysregulation in patients. However, it would be important to stress that the furin site is critical for the activation of ENaC. If this activation site is blocked by mimicry of the unique S1/S2 cleavage site, its likely consequence would be very low ENaC activity on the surface of the airways, compromising severely fluid reabsorption, which can explain an important lung phenotype observed in COVID19. The so called "wet lung" syndrome, that can occur in premature babies because ENaC is only fully expressed at the time of birth, should be mentioned to support this contention. The PHA Type 1 case described in Welzel et al., 2013, also sup-ports the importance of the furin site for ENaC activation. We thank the reviewer for this feedback. We have now revised the text accordingly. “Among many reported loss-of-function mutations in ENaC-ɑ associated with Pseudohypoaldosteronism type 1 (PHA1), a frameshift mutation leading to a premature stop codon in Serine-205 at the 5th position of the ENaC-ɑ mimicked peptide (RRAR|SVAS) is also known to cause this monogenic disease (Welzel et al., 2013). […] Indeed, the exact mechanism of SARS-CoV-2’s potential hijack of ENaC activation needs to be investigated.” Additional issues: 1) The Authors reported in Figure 2—figure supplement 5 ENaC expression in the proximal tubule, which is wrong as ENac is expressed only in the aldosterone sensitive distal nephron (ASDN) (Distal Convoluted Tubule DCT2, Connecting Tubule CNT and Collecting Duct CD). We thank the authors for pointing this out. Figure 2—figure supplement 5 has now been updated to include the principal cells from collecting duct along with connecting tubule cells. Although both these cell-types express high levels of ENAC-α (58% and 47%), ACE2 expression was not detected in these cells. In contrast, only 2.77% of the proximal tubule cells had detectable expression of SCNN1A, but a higher percentage (8.46%) of these cells were also observed to express ACE2. 2) References should be better placed and selected. For example in the second paragraph, last sentence: the structure of human ENaC (Noreng et al., 2018) should be cited here and not in the third paragraph where earlier work on structure by Vallet et al., 1997 or by Orce et al., 1980 should be cited. We now have updated the references as suggested. 3) The title is too generic and should mention ENaC rather than “a cleavable pulmonary renal peptide”. We thank the reviewer for this feedback. We have now updated the title to: “SARS-CoV-2 strategically mimics proteolytic activation of human ENaC”.
  21 in total

1.  Epithelial sodium channels are activated by furin-dependent proteolysis.

Authors:  Rebecca P Hughey; James B Bruns; Carol L Kinlough; Keri L Harkleroad; Qiusheng Tong; Marcelo D Carattino; John P Johnson; James D Stockand; Thomas R Kleyman
Journal:  J Biol Chem       Date:  2004-03-07       Impact factor: 5.157

2.  Five novel mutations in the SCNN1A gene causing autosomal recessive pseudohypoaldosteronism type 1.

Authors:  Maik Welzel; Leyla Akin; Anja Büscher; Tülay Güran; Berthold P Hauffa; Wolfgang Högler; Julia Leonards; Beate Karges; Heiner Kentrup; Birgul Kirel; Emine Esin Yalinbas Senses; Neslihan Tekin; Paul-Martin Holterhus; Felix G Riepe
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

3.  An epithelial serine protease activates the amiloride-sensitive sodium channel.

Authors:  V Vallet; A Chraibi; H P Gaeggeler; J D Horisberger; B C Rossier
Journal:  Nature       Date:  1997-10-09       Impact factor: 49.962

4.  Distinct pools of epithelial sodium channels are expressed at the plasma membrane.

Authors:  Rebecca P Hughey; James B Bruns; Carol L Kinlough; Thomas R Kleyman
Journal:  J Biol Chem       Date:  2004-10-04       Impact factor: 5.157

5.  Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites.

Authors:  Sandrine Belouzard; Victor C Chu; Gary R Whittaker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

Review 6.  Mechanisms of coronavirus cell entry mediated by the viral spike protein.

Authors:  Sandrine Belouzard; Jean K Millet; Beth N Licitra; Gary R Whittaker
Journal:  Viruses       Date:  2012-06-20       Impact factor: 5.048

7.  The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database.

Authors:  Neil D Rawlings; Alan J Barrett; Paul D Thomas; Xiaosong Huang; Alex Bateman; Robert D Finn
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

8.  Structure of the human epithelial sodium channel by cryo-electron microscopy.

Authors:  Sigrid Noreng; Arpita Bharadwaj; Richard Posert; Craig Yoshioka; Isabelle Baconguis
Journal:  Elife       Date:  2018-09-25       Impact factor: 8.140

9.  Data, disease and diplomacy: GISAID's innovative contribution to global health.

Authors:  Stefan Elbe; Gemma Buckland-Merrett
Journal:  Glob Chall       Date:  2017-01-10

10.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.

Authors:  Alexandra C Walls; Young-Jun Park; M Alejandra Tortorici; Abigail Wall; Andrew T McGuire; David Veesler
Journal:  Cell       Date:  2020-03-09       Impact factor: 41.582

View more
  44 in total

1.  SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases.

Authors:  Gonzalo Ferreira; Axel Santander; Florencia Savio; Mariana Guirado; Luis Sobrevia; Garth L Nicolson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-09-03       Impact factor: 5.187

2.  Potential therapeutic effects of Ivermectin in COVID-19.

Authors:  Nastaran Barati; Seyedmousa Motavallihaghi; Banafsheh Nikfar; Shahla Chaichian; Amir Abbas Momtazi-Borojeni
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-10

3.  How signalling games explain mimicry at many levels: from viral epidemiology to human sociology.

Authors:  William Casey; Steven E Massey; Bud Mishra
Journal:  J R Soc Interface       Date:  2021-02-24       Impact factor: 4.118

Review 4.  Inter-proteomic posttranslational modifications of the SARS-CoV-2 and the host proteins ‒ A new frontier.

Authors:  Suresh Mishra; Geetika Bassi; Bl Grégoire Nyomba
Journal:  Exp Biol Med (Maywood)       Date:  2021-01-19

5.  Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis.

Authors:  Tyler Wagner; Fnu Shweta; Karthik Murugadoss; Samir Awasthi; A J Venkatakrishnan; Sairam Bade; Arjun Puranik; Martin Kang; Brian W Pickering; John C O'Horo; Philippe R Bauer; Raymund R Razonable; Paschalis Vergidis; Zelalem Temesgen; Stacey Rizza; Maryam Mahmood; Walter R Wilson; Douglas Challener; Praveen Anand; Matt Liebers; Zainab Doctor; Eli Silvert; Hugo Solomon; Akash Anand; Rakesh Barve; Gregory Gores; Amy W Williams; William G Morice; John Halamka; Andrew Badley; Venky Soundararajan
Journal:  Elife       Date:  2020-07-07       Impact factor: 8.140

Review 6.  Why All the Fury over Furin?

Authors:  Essam Eldin A Osman; Alnawaz Rehemtulla; Nouri Neamati
Journal:  J Med Chem       Date:  2021-08-02       Impact factor: 7.446

Review 7.  Role of Serine Proteases and Host Cell Receptors Involved in Proteolytic Activation, Entry of SARS-CoV-2 and Its Current Therapeutic Options.

Authors:  Gashaw Dessie; Tabarak Malik
Journal:  Infect Drug Resist       Date:  2021-05-24       Impact factor: 4.003

Review 8.  Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection.

Authors:  K A Dvornikova; E Yu Bystrova; L P Churilov; A Lerner
Journal:  Mol Biol Rep       Date:  2021-07-22       Impact factor: 2.742

9.  A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry.

Authors:  Yanwen Chen; Travis Lear; John Evankovich; Mads Larsen; Bo Lin; Irene Alfaras; Jason Kennerdell; Laura Salminen; Daniel Camarco; Karina Lockwood; Jie Liu; Michael Myerburg; John McDyer; Yuan Liu; Toren Finkel; Bill Chen
Journal:  Res Sq       Date:  2020-08-14

10.  A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry.

Authors:  Yanwen Chen; Travis B Lear; John W Evankovich; Mads B Larsen; Bo Lin; Irene Alfaras; Jason R Kennerdell; Laura Salminen; Daniel P Camarco; Karina C Lockwood; Ferhan Tuncer; Jie Liu; Michael M Myerburg; John F McDyer; Yuan Liu; Toren Finkel; Bill B Chen
Journal:  Nat Commun       Date:  2021-06-23       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.